Tupy (TUPY3) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
20 Mar, 2026Executive summary
Net revenue declined 9% to R$ 9.7 billion in 2025, mainly due to lower production and sales volumes amid global uncertainties, with a significant EBITDA drop and net loss driven by R$ 544 million in restructuring-related impacts.
Strategic execution focused on capacity optimization, cost reduction, and new business growth, with R$ 915 million in operating cash generation and R$ 300 million in cost and expense reductions.
MWM subsidiary improved EBITDA margin to 10%, up from 8% in 2024, and contributed 27% of consolidated net revenue.
Financial highlights
Revenue declined 12% year-over-year to R$ 9,693 million in 2025, with Q4 revenue at R$ 2.2 billion, down 12% year-over-year.
Adjusted EBITDA fell to R$ 661 million (6.8% margin), with traditional business margin at 5% and net income at -R$ 655 million, impacted by non-recurring write-downs.
Net debt at year-end was R$ 2.2 billion, with leverage at 3.35x EBITDA for the last 12 months.
Cash position at year-end was R$ 1.9 billion, reinforcing liquidity.
Operating cash flow reached R$ 915 million, supported by working capital initiatives and sale of IPI tax-credit premium.
Outlook and guidance
Expectation of above-market growth in 2026, driven by new project ramp-ups, margin expansion, and recurring EBITDA gains of R$ 180 million annually from 2027.
Deleveraging anticipated as of H2 2026, supported by new projects and efficiency gains.
Positive 2026 outlook for external markets, with reduced uncertainties, EPA 27 confirmation, and improved freight rates expected to drive demand.
Ongoing capacity reduction and flexibility initiatives expected to yield R$ 100 million in savings in 2026 and R$ 180 million annually from 2027.
North American and European markets show positive signs, while Brazil remains more uncertain due to high interest rates and weak agribusiness.
Latest events from Tupy
- Record EBITDA and cash flow offset lower revenue; new contracts and bioplants drive growth.TUPY3
Q2 20242 Feb 2026 - Record cash flow and margin gains offset revenue and net income declines amid weak demand.TUPY3
Q3 202414 Jan 2026 - Record EBITDA and cash flow achieved despite lower sales, with margin gains and strong outlook.TUPY3
Q4 202423 Dec 2025 - Revenue fell 6% and EBITDA margin dropped, but net income rose 33% on financial gains.TUPY3
Q2 202523 Nov 2025 - Revenue down 4% and net loss, but aftermarket and gensets segments showed strong growth.TUPY3
Q1 202520 Nov 2025 - Revenue and EBITDA fell, but record cash flow and new segments support future margin gains.TUPY3
Q3 202513 Nov 2025